Image

IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Testing Darovasertib and Crizotinib for metastatic eye cancer treatment.

Recruiting
18 years and older
All
Phase 2/3
  • Simplified description (AI rewritten)
  • Technical description (Original)

Study Overview: This research is for patients with metastatic uveal melanoma (MUM), a type of eye cancer that spreads to other parts of the body. Participants must be HLA-A*02:01 negative, meaning they lack a specific protein marker. Two medicines, IDE196 and crizotinib, are being tested together to see if they work better than standard treatments like pembrolizumab, ipilimumab + nivolumab, or dacarbazine.

Study Details: The study has multiple stages. First, two doses of IDE196 with crizotinib will be tested to find the best one. Then, more participants will get the chosen dose to see how well it fights cancer. This study will last through several phases to ensure the safety and effectiveness of the treatment.

  • Length of Study: Ongoing with multiple phases.
  • Visits Needed: Regular visits for treatment and monitoring are required.
  • Risks: Includes typical risks of cancer treatment and possible side effects.

If you're eligible, the study offers a chance to try a new treatment before it's widely available. It's important to discuss with your doctor to understand all potential benefits and risks.

Print
Study details
    Metastatic Uveal Melanoma

NCT05987332

IDEAYA Biosciences

5 April 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.